Table 1.
Summary of Included Studies
| Study Information | Procedure Characteristics | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Author | Study Period | Region | Design | TAVR (n) | Edwards, n (%) | Medtronic, n (%) | TF, n (%) | TA, n (%) | Follow-Up | STS Score (%) |
| Martinez, GJ10 | 2009.6 to 2013.7 | Australia | Single center | 100 | 98 (98) | 2 (2) | 68 (68) | 32 (32) | Mean 17 months | — |
| Stabile, E11* | 2010.4 to 2011.4 | Italy | Single center | 60 | 120 (100) | 0 | — | 6 months | 10.4±6.8/9.7±5.1 | |
| Omer, S12 | 2011.12 to 2012.12 | US | Single center | 19 | 19 (100) | 0 | 19 (100) | 0 | Mean 8.8±3.9 months | 8.8±10.7 |
| Noble, S13 | 2008.8 to 2012.11 | Switzerland | Single center | 23 | 1 (4.3) | 19 (82.6) | 21 (91.3) | — | Mean 408±294 days | 8.7±2.9 |
| Walther, T14 | 2009.9 to 2010.8 | European | PREVAIL transapical study | 150 | 150 (100) | 0 | 0 | 150 (100) | 1 year | 7.5±4.4 |
| Latib, A15 | 2007.11 to 2011.2 | Italy | Single center | 111 | 70 (63) | 41 (37) | 111 (100) | 0 | 1 year | 4.57±2.28 |
| Yamamoto, M16 | 2007.12 to 2011.6 | Japan | Single center | 26 | 2 (7.7) | 24 (92.3) | 24 (92.3) | 0 | 6 months | 13.4±7.2 |
| Wendler, O17 | 2007.11 to 2009.12 | European | SOURCE | 1387 | 1387 (100) | 0 | 0 | 1387 (100) | 2 years | — |
| Wendler, O18 | 2009.12 to 2011.2 | Mixed | Multi centers | 120 | 120 (100) | 0 | — | — | 6.8±4.0 | |
| Kempfert, J19 | 2009.11 to 2010.8 | Germany | Single center | 40 | 0 | 0 | 0 | 40 (100) | 6 months | 9.0±4.7 |
| Van Mieghem, NM20 | 2005.11 to 2011.12 | Netherlands | Single center | 237 | 12 (5) | 222 (94) | 228 (96) | 3 (1) | Median 13 months | — |
| Doss, M21 | 2005.1 to 2008.12 | Germany | Single center | 100 | 100 (100) | 0 | 0 | 100 (100) | 3.8±2 years | 16±3 |
| Ducrocq, G22† | 2006.10 to 2010.6 | France | Single center | 201 | 171 (85) | 30 (15) | 131 (65) | 61 (30) | Mean 7±9 months | — |
| Ussia, GP23 | 2007.6 to 2008.8 | Italy | Italian CoreValve registry | 181 | 0 | 181 (100) | 172 (95) | 0 | 3 years | 11.4±9.9 |
| D’Onofrio, A24 | 2008.4 to 2010.11 | Italy | I-TA | 504 | 504 (100) | 0 | 0 | 504 (100) | Mean 9.2±6.5 months | 11±4 |
| Bosmans, JM25 | Until April 2010 | Belgium | Belgian TAVR Registry | 328 | 187 (57) | 141 (43) | 232 (71) | 88 (27) | 1 year | — |
| Hernández-Antolín, RA26 | 2007.5 to 2010.4 | Spain | Single center | 76 | 50 (66) | 26 (34) | 76 (100) | 0 | 367±266 days for ES; 172±159 days for MCV | 6.34±1.8 |
| Johansson, M27 | 2008.1 to 2009.11 | Sweden | Single center | 40 | 40 (100) | 0 | 10 (25) | 30 (70) | Mean 10±8 months | — |
| Lefèvre, T28 | 2007.4 to 2008.1 | European | European PARTNER | 130 | 130 (100) | 0 | 61 (47) | 69 (53) | 1 year | 11.6±6.5 |
| Leon, MB29‡ | 2007.5 to 2009.3 | Mixed | PARTNER | 179 | 179 (100) | 0 | 179 (100) | 0 | 1 year | 11.2±5.8 |
| Drews, T30 | 2008.4 to 2010.1 | Germany | Single center | 158 | 198 (100) | 0 | 0 | 198 (100) | — | 21±16.3/29±18.1 |
| Attias, D31† | 2006.10 to 2009.6 | France | Single center | 83 | 72 (87) | 11 (13) | 83 (100) | 0 | Median 9 months | 15±8 |
| Ye, J32 | 2005.10 to 2009.2 | Canada | Single center | 71 | 71 (100) | 0 | 0 | 71 (100) | 3 years | 12.1±7.7 |
| Guinot, PG33† | 2006.10 to 2009.2 | France | Single center | 90 | — | 62 (69) | 28 (31) | — | 15 (11 to 23) | |
| Avanzas, P34 | 2007.12 to 2009.7 | Spain | Multi centers | 108 | 0 | 108 (100) | 103 (95) | 0 | Average 7.6 months | — |
| Kapadia, SR35 | 2006.2 to 2007.3 | US | Single center | 18 | — | 278±128 days | 11.4±7.5 | |||
| Walther, T36 | 2006.2 to 2008.3 | Germany | Single center | 25 | 25 (100) | 0 | 0 | 25 (100) | Mean 351 days | 17 (6 to 43) |
| Webb, JG37 | — | Canada | Single center | 50 | 50 (100) | 0 | 50 (100) | 0 | Median 359 days | — |
I-TA indicates Italian registry of transapical aortic valve implantation; MCV indicates Medtronic CoreValve; STS, Society of Thoracic Surgeons; TA-TAVR, transapical TAVR; TAVR, transcatheter aortic valve replacement; TF-TAVR, transfemoral TAVR.
*
Randomized by single or double antiplatelet therapy after the procedure.
†
These 3 studies shared an overlapping case series. The study by Ducrocq, G et al was used for overall analysis. The study by Attias, D et al was used for TF-TAVR subgroup analysis. The study by Guinot, P et al was used for TA-TAVR subgroup analysis.
‡
Inoperable patients were randomly assigned to standard therapy (including balloon aortic valvuloplasty) or TF-TAVR.